Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Fluorescent Label Passes Through Blood-Brain Barrier
Disease Discoveries

Fluorescent Label Passes Through Blood-Brain Barrier

By Will DossAug 23, 2021
Share
Facebook Twitter Email
Irina Balyasnikova, PhD, associate professor of Neurological Surgery (left), was senior author of the study published in ACS Nano.

Fluorescent indocarbocyanine lipid (ICL) shows much better distribution within glioblastoma brain tumors compared to fluorescent phospholipids, according to a study published in ACS Nano.

Finding compounds that can effectively penetrate the blood-brain barrier is a major challenge in glioblastoma research, so these findings can help guide scientists in future experiments and also hint at the underlying mechanisms governing barrier permeability, according to Irina Balyasnikova, PhD, associate professor of Neurological Surgery and co-senior author of the study.

“The continuous penetration and distribution of ICLs should have implications for how we formulate these compounds,” said Balyasnikova, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

The study was a collaboration between Balyasnikova and Dmitri Simberg, PhD, associate professor of pharmaceutical sciences at the University of Colorado and co-senior author of the study.

Liposomes, spherical vesicles comprised of phospholipid layers, are one of the most commonly used nano-scale drug delivery platforms. Mimicking the structure of ordinary cell membranes, liposomes’ water solubility and biodegradability make them a popular choice for cancer therapeutic delivery.

Liposomes exhibit good tumor uptake in many types of cancer, but have trouble with glioblastoma, according to Balyasnikova.

“Glioblastoma is hidden behind the blood-brain barrier, and most drugs and nanoparticles cannot efficiently penetrate and distribute behind the barrier,” Balyasnikova said.

In the current study, scientists labeled liposomes with both the ICL label or fluorescent phospholipid (FPL) label in the same liposome, and compared their penetration in models of glioblastoma, breast cancer and and head and neck cancer. While both labels initially localized in and around tumor blood vessels, the ICL label spread over a significantly larger tumor area — even past the blood-brain barrier.

“You could see them homogenously penetrating the tumor in the model,” Balyasnikova said.

This is useful for tracking the spread of anti-cancer treatments, both in experiments and potentially in future treatments, according to Balyasnikova. Further, the ICL label was taken up by tumor-associated macrophages. Uptake by macrophages is especially important in the context of glioblastoma, as glioblastoma-associated macrophages are heavily implicated in treatment resistance due to the immune-suppressive environment they generate in the brain.

“The next step for our collaborative effort is to use ICLs to deliver drugs that either kill these macrophages or prevent them from generating this immune-suppressive phenotype, and then this could be a great system,” Balyasnikova said. “This could be a great addition to immunotherapy for glioblastoma.”

The study was supported by National Institutes of Health grants R01CA194058, R33NS101150, R01NS106379 and R01NS122395.

Cancer Research
Share. Facebook Twitter Email

Related Posts

Coaxing Hair Growth in Aging Hair Follicle Stem Cells

Jun 9, 2023

New Therapeutic Target for Osteoarthritis Identified 

Jun 9, 2023

Largest Cell Map of Human Lung Reveals Insights Into Disease

Jun 8, 2023

Comments are closed.

Latest News

Coaxing Hair Growth in Aging Hair Follicle Stem Cells

Jun 9, 2023

New Therapeutic Target for Osteoarthritis Identified 

Jun 9, 2023

Largest Cell Map of Human Lung Reveals Insights Into Disease

Jun 8, 2023

McNally Honored with Walder Award

Jun 8, 2023

Biological Aging Increases Risk of Depression, Anxiety in Adults 

Jun 7, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
ANB05555
ANB08990
ANB09022
ANB09063
ANB09008
ANB08781
ANB08971
ANB09000
ANB08992
ANB09015
ANB09058
ANB09048

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.